Edition:
United Kingdom

argenx NV (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

48.39EUR
15 Dec 2017
Change (% chg)

€-5.11 (-9.55%)
Prev Close
€53.50
Open
€50.94
Day's High
€50.94
Day's Low
€45.06
Volume
192,172
Avg. Vol
41,327
52-wk High
€57.48
52-wk Low
€14.55

Summary

Name Age Since Current Position

Peter Verhaeghe

Chairman of the Supervisory Board

Tim Van Hauwermeiren

Chief Executive Officer

Eric Castaldi

Chief Financial Officer

Hans de Haard

Chief Scientific Officer

Debbie Allen

Senior Director, Business Development

Torsten Dreier

Chief Development Officer

Jacobus Rasser

IP Counsel

Michael Saunders

Senior Director Targets & Programs

Alain Thibault

Chief Medical Officer

John de Koning

Member of the Supervisory Board

David Lacey

Member of the Supervisory Board

Werner Lanthaler

49 Member of the Supervisory Board

Bruno Montanari

Member of the Supervisory Board

Michael Sheffery

Member of the Supervisory Board

Christina Takke

44 Member of the Supervisory Board

Harrold van Berlingen

Member of the Supervisory Board

Biographies

Name Description

Peter Verhaeghe

Mr. Peter Verhaeghe is Chairman of the Supervisory Board of arGEN-X BV. He earned his degree in Law from the University of Leuven in 1981, where he graduated magna cum laude. From 1981 to 1983, he was an assistant professor of tax law at the University of Leuven. He earned his LL.M. at Harvard Law School in 1984. Mr. Verhaeghe is a partner in charge of the corporate finance law and tax sections of Vermulst Verhaeghe & Graafsma.

Tim Van Hauwermeiren

Mr. Tim Van Hauwermeiren is Chief Executive Officer of arGEN-X BV. Tim has 18 years of business development and operational management experience within the biotech and consumer goods sectors. During which time he has played a key role in a number of fund raisings, IPO and the negotiation of a number of major licensing deals. Prior to becoming CEO of arGEN-X, he was senior Business Development Manager at Ablynx NV where we was part of the team that negotiated a $265 million research & development deal with Boehringer Ingelheim in 2007. Prior to joining Ablynx, Tim held various management positions with the Procter & Gamble Company in R&D and Business Development, where he conceived and developed several new products. Among those was a healthcare innovation which won the United Nations ICC World Business Award in 2004. Tim holds a Master of Science degree in Bio-engineering from the University of Gent (Belgium) and received general management training at INSEAD and The Vlerick School of Management (Executive MBA).

Eric Castaldi

Mr. Eric Castaldi serves as Chief Financial Officer at arGEN-X B.V. Mr. Castaldi has 27 years of international financial executive management experience, including 18 years in the biopharmaceutical industry. Before joining arGEN-X, Mr. Castaldi was CFO from 1998 to 2013 at Nicox, a Euronext-listed biotech company. At Nicox, he was a member of the Executive committee and participated in all the financings of the company since its IPO in November 1999. From 2008 to 2012 he also served as board member and chairman of the audit committee of Hybrigenics, a French biopharmaceutical company specialized in oncology and listed on Euronext. Prior to this he was CFO at Safety Kleen Corporation, a US-based environmental waste company, where he was responsible for operations in France and Belgium. From 1989 through 1997, he was CFO in charge of French and German operations, at My Kinda Town plc, a European leisure company. During that period, he was involved in the 1994 flotation of that company on the London Stock Exchange. From 1986 through 1989, he was employed as Financial Analyst at the Research and Development Centre, located in Sophia Antipolis, of Cordis Corporation, a US-based company specialized in bio-surgical instrumentation. He graduated in Finance, Accountancy and Administration from the University of Nice in 1986.

Hans de Haard

Prof. Hans de Haard is the Chief Scientific Officer of arGEN-X BV. From 2002 until he joined arGEN-X, he worked at Ablynx NV as Director Technology Development, and latterly as Senior Director Discovery Research. He holds a Master's of Science degree in biochemistry and a Doctoral degree in molecular immunology from the University of Maastricht, Netherlands. He is Professor of Camelid Immunology at Utrecht University, Netherlands.

Debbie Allen

Ms. Debbie Allen, Ph.D. serves as Senior Director, Business Development at arGEN-X B.V. Debbie has been active in the antibody engineering field since the 1980s. She brings to arGEN-X more than 30 years of corporate and business development experience with small and large biotech companies focused on biopharmaceuticals. She established her Business Development career at Cambridge Antibody Technology (now MedImmune), where she had management responsibility for technology, intellectual property and product out-licensing, corporate equity, co-development and cross-license agreements. She was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the monoclonal antibody drug BENLYSTA (belimumab), now approved for the treatment of systemic lupus erythematosus. Prior to joining arGEN-X, Debbie acted for eight years as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support.

Torsten Dreier

Dr. Torsten Dreier is the Chief Development Officer of arGEN-X BV. He holds a Doctoral degree in biochemistry from the University of Tubingen, Germany. In 1997, he joined Micromet AG in Munich, Germany. He became Director of Preclinical Development. In 2003, he joined Ablynx NV as Director Therapeutic Drug Development and later became Senior Director Preclinical Development, with overall responsibility for pharmacology, toxicology, bioanalytics and CMC as well as early clinical development.

Jacobus Rasser

Michael Saunders

Dr. Michael Saunders is Senior Director, Targets & Programs of arGEN-X BV. He has twenty years of small molecule and biological drug discovery experience from both pharmaceutical and biotechnology, spanning several therapeutic areas. He has experience in target selection, project leadership, and project management. He holds a Doctoral degree from University of North Carolina in United States, a Bachelor of Arts in natural sciences from Cambridge University in United Kingdom, and an Executive Master's in Business Administration from ESSEC business school in Germany.

Alain Thibault

Dr. Alain Thibault serves as Chief Medical Officer of arGEN-X BV. He has clinical development experience in oncology, both in the United States and Europe. Prior to joining arGEN-X, he was therapeutic area head of Oncology at Regeneron Pharmaceuticals where he was responsible for clinical development, product strategy and portfolio management, as well as coordination of the collaboration with Sanofi to develop fully human antibody products for multiple cancer indications. He previously held senior research positions at Johnson & Johnson and Hoffman-La Roche before joining Regeneron. Dr. Thibault holds a Doctorate of Medicine from the McGill University (Canada).

John de Koning

Dr. John de Koning is Member of the Supervisory Board of arGEN-X BV. Dr. de Koning is Partner at LSP (Life Sciences Partners), an independent European investment firm, providing financing to private and public life-science companies. He serves or has served on the supervisory boards of arGEN-X, BMEYE (acquired by Edwards Lifesciences), Innovative Biosensors Inc., Merus, Pronota, Prosensa, and Skyline Diagnostics. Dr. de Koning has a Master’s degree in Molecular Biology from the University of Utrecht and a PhD in Oncology from the Erasmus University of Rotterdam.

David Lacey

Dr. David L. Lacey is Member of the Supervisory Board of arGEN-X BV. He moved from academia to an industry setting when he joined Amgen. During the last five years of his tenure he assumed the head of Discovery Research (> 1200 FTEs) for Amgen. In this capacity, he charted the course and motivated a diverse senior team of scientific leaders from different disciplines as well as engaging and managing a diverse stakeholder network. At any given time there were over 100 actively managed preclinical projects across four therapeutic areas: hematology/oncology, inflammation, metabolic disorders, and neuroscience.

Werner Lanthaler

Dr. Werner Lanthaler is Member of the Supervisory Board of arGEN-X BV. He is currently Chief Executive Officer of Evotec (Frankfurt Stock Exchange: EVT), a role he took in March 2009. Under his leadership Evotec has become one of the drug discovery research organisations globally. He holds a doctorate in Business Administration from Vienna University of Economics and Business, earned a Master's degree from Harvard University, and holds a degree in Psychology.

Bruno Montanari

Dr. Bruno Montanari is Member of the Supervisory Board of arGEN-X BV. He is a Director at Omnes Capital's Life Sciences Venture Capital team, which he joined in January 2010. He began his career in 1999 in London as an Investment Banker in the Healthcare Groups of Deutsche Bank and Merrill Lynch, later joining the venture capital community first with CDP Capital and then Atlas Venture, responsible for several European portfolio companies in the biotech and medtech areas as board member or observer.

Michael Sheffery

Dr. Michael Sheffery is Member of the Supervisory Board of arGEN-X BV. He is a founding General Partner of healthcare investment firm OrbiMed. He was formerly Head of the Laboratory of Gene Structure and Expression at Memorial Sloan-Kettering Cancer Center.

Christina Takke

Dr. Christina Takke is Member of the Supervisory Board of arGEN-X BV. She is a Partner with Forbion Capital Partners (previously ABN AMRO Capital Life Sciences) and joined the group in 2000. Dr. Takke joined the ABN AMRO Capital Life Sciences team as an analyst in 2000, progressing to the position of Principal before being promoted to Partner.

Harrold van Berlingen

Dr. Harrold van Berlingen is Member of the Supervisory Board of arGEN-X BV. He is the Managing Director and Founder of Thuja Capital. He headed the life sciences effort of AlpInvest Partners managing a portfolio of over 30 companies, prior to founding Thuja Capital in 2006. Dr. van Barlingen joined AlpInvest Partners in 2001, from the Boston Consulting Group (BCG), where he worked as a consultant in management and strategy. Before BCG, he was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an internationally active firm specialized in the field of health economics.